Biopharma dive · 1d ago
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.
Rhyter Times aggregates short excerpts. The full story is reported by Biopharma dive.
Read the full story at Biopharma dive →